On Thursday, Shares of PennantPark Investment Corp. (NASDAQ:PNNT), gained 0.26% to $7.57.
PennantPark Investment Corporation, declared fourth fiscal quarter 2015 distribution of $0.28 per share, payable on October 1, 2015 to stockholders of record as of September 21, 2015. Distributions are paid from taxable earnings and may comprise return of capital and/or capital gains. The specific tax characteristics of the distribution will be stated to stockholders on Form 1099 after the end of the calendar year and in the Company’s periodic report filed with the Securities and Exchange Commission.
PennantPark Investment Corporation is a publicly listed business development firm specializing in direct and mezzanine investments in middle market companies. It invests in the form of mezzanine debt, senior secured loans, and equity investments.
Shares of Steven Madden, Ltd. (NASDAQ:SHOO), inclined 0.50% to $40.29, during its last trading session.
Steve Madden, declared that the company will be presenting at the Goldman Sachs 22nd Annual Global Retailing Conference held at The Plaza Hotel in New York City on Wednesday, September 9, 2015 at 11:20 am Eastern Time. Edward Rosenfeld, Chairman and Chief Executive Officer, will host the presentation.
Steven Madden, Ltd. designs, sources, markets, and sells fashion-forward name brand and private label footwear for women, men, and children. Its Wholesale Footwear segment provides footwear under Steve Madden Women’s, Madden Girl, Steve Madden Men’s, Dolce Vita, DV by Dolce Vita, Mad Love, Steven by Steve Madden, Report, Report Signature, Superga, Betsey Johnson, Steve Madden Kids, FREEBIRD by Steven, Stevies, Wild Pair, Brian Atwood, and B Brian Atwood brands, in addition to under the third party brands.
At the end of Thursday’s trade, Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART), gained 3.57% to $62.39.
Integra LifeSciences Holdings Corporation and Tornier N.V., declared a definitive agreement under which Integra will acquire the United States rights to Tornier’s Salto Talaris(R) and Salto XT(TM) ankle replacement products and Tornier’s Futura(TM) silastic toe replacement products, for an unrevealed cash payment. The agreement also comprises an option to purchase, in the future, the rights to the Salto Talaris(R), Salto XT(TM), Salto Mobile(TM), and Futura(TM) silastic toe replacement products outside the United States.
The transaction is subject to approval by the United States Federal Trade Commission (FTC) and the closure of the pending merger of Tornier and Wright Medical Group, Inc. which, pending FTC clearance is predictable to occur in the third quarter of 2015.
“This acquisition broadens our extremity product portfolio by adding commercially available products,” said Mark Augusti, President of Integra’s Orthopedics, and Tissue Technologies business. “It allows us to diversify our lower extremity portfolio and accelerates our entry into the U.S. total ankle replacement segment of the foot and ankle market.”
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International.
Finally, Axcelis Technologies Inc (NASDAQ:ACLS), ended its last trade with -0.62% loss, and closed at $3.22.
Axcelis Technologies declared that Company administration will present at the Craig-Hallum 6th Annual Alpha Select Conference on September 17, 2015 at 9:20 a.m. in New York City.
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips worldwide. It provides offers a line of high energy, high current, and medium current implanters for all application requirements.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
